# Pediatric Neurology: A Comprehensive Guide for Medical Students

[![License: CC BY-NC-SA 4.0](https://img.shields.io/badge/License-CC%20BY--NC--SA%204.0-lightgrey.svg)](https://creativecommons.org/licenses/by-nc-sa/4.0/)

**Korea University Medical Center (KUMC)**
**Department of Pediatric Neurology**
**Last Updated: 2024**

---

## Table of Contents

1. [Introduction](#1-introduction)
2. [Seizure Fundamentals](#2-seizure-fundamentals)
3. [ILAE Classification of Epilepsy](#3-ilae-classification-of-epilepsy)
4. [Electroencephalography (EEG)](#4-electroencephalography-eeg)
5. [Seizures in the Genetic Era](#5-seizures-in-the-genetic-era)
6. [Medical Evaluation and Diagnostic Workup](#6-medical-evaluation-and-diagnostic-workup)
7. [Physical Examination and Phenotyping](#7-physical-examination-and-phenotyping)
8. [Precision Medicine in Epilepsy](#8-precision-medicine-in-epilepsy)
9. [Clinical Pearls and Pitfalls](#9-clinical-pearls-and-pitfalls)
10. [Summary: Approach to Pediatric Neurologic Diseases](#10-summary-approach-to-pediatric-neurologic-diseases)
11. [Learning Objectives and Self-Assessment](#11-learning-objectives-and-self-assessment)
12. [References and Further Reading](#12-references-and-further-reading)

---

## 1. Introduction

Pediatric neurology encompasses disorders of the nervous system in children, from neonates to adolescents. The developing brain presents unique challenges and opportunities for diagnosis and treatment. This lecture provides a systematic approach to understanding seizures and epilepsy in the pediatric population, with emphasis on the modern genetic era and precision medicine.

### Why This Matters

- **Prevalence**: Epilepsy affects approximately 0.5-1% of children worldwide
- **Impact**: Seizures can significantly affect neurodevelopment and quality of life
- **Opportunity**: Early accurate diagnosis enables targeted therapy and improved outcomes

---

## 2. Seizure Fundamentals

### 2.1 Definitions

| Term | Definition |
|------|------------|
| **Seizure** | A transient occurrence of signs/symptoms due to abnormal excessive or synchronous neuronal activity in the brain |
| **Epilepsy** | A disease characterized by an enduring predisposition to generate epileptic seizures (‚â•2 unprovoked seizures >24h apart, or 1 seizure with high recurrence risk ‚â•60%) |
| **Status Epilepticus** | A seizure lasting >5 minutes, or multiple seizures without full recovery between them |

### 2.2 Seizure Semiology

Understanding seizure onset and evolution is critical for:
- **Localization**: Identifying the epileptogenic zone
- **Classification**: Determining seizure type
- **Treatment Selection**: Guiding appropriate medication choice
- **Surgical Planning**: When applicable

### 2.3 Key Questions for Seizure History

```
‚ñ° What was the patient doing before the seizure?
‚ñ° Was there any warning (aura)?
‚ñ° Where did the movements start? (focal vs. generalized onset)
‚ñ° What was the sequence of events?
‚ñ° Was there loss of awareness?
‚ñ° How long did each phase last?
‚ñ° What was the postictal state?
‚ñ° Were there any triggers? (fever, sleep deprivation, photic)
```

---

## 3. ILAE Classification of Epilepsy

The International League Against Epilepsy (ILAE) provides the standardized framework for epilepsy classification.

### 3.1 Three Levels of Diagnosis (2017 Framework)

```
Level 1: SEIZURE TYPE
    ‚Üì
Level 2: EPILEPSY TYPE
    ‚Üì
Level 3: EPILEPSY SYNDROME
```

### 3.2 Updated Seizure Classification (2025)

The [ILAE updated classification](https://www.ilae.org/guidelines/guidelines-and-reports/updated-classification-of-epileptic-seizures-position-paper-of-the-international-league-against-epilepsy) maintains four main classes:

| Class | Description |
|-------|-------------|
| **Focal** | Originates in networks limited to one hemisphere |
| **Generalized** | Originates at some point within, and rapidly engaging, bilateral networks |
| **Unknown** | Cannot be determined whether focal or generalized |
| **Unclassified** | Inadequate information or unusual features |

#### Focal Seizures - Key Classifiers

- **Awareness**: Retained vs. Impaired
- **Motor onset**: Automatisms, atonic, clonic, epileptic spasms, hyperkinetic, myoclonic, tonic
- **Non-motor onset**: Autonomic, behavior arrest, cognitive, emotional, sensory

#### Generalized Seizures

- **Motor**: Tonic-clonic, clonic, tonic, myoclonic, atonic, epileptic spasms
- **Non-motor (Absence)**: Typical, atypical, myoclonic, eyelid myoclonia

### 3.3 Epilepsy Syndromes (2022 ILAE Classification)

The [2022 ILAE position papers](https://onlinelibrary.wiley.com/doi/10.1111/epi.17241) established consensus criteria for epilepsy syndromes:

#### Syndromes by Age of Onset

**Neonates and Infants (0-2 years)**
- Self-limited neonatal epilepsy
- Self-limited familial neonatal epilepsy
- Early infantile DEE (e.g., Ohtahara syndrome)
- Epilepsy of infancy with migrating focal seizures
- Infantile epileptic spasms syndrome (West syndrome)
- Dravet syndrome

**Childhood**
- *Self-limited focal epilepsies:*
  - Self-limited epilepsy with centrotemporal spikes (SLECTS/Rolandic)
  - Self-limited epilepsy with autonomic seizures (Panayiotopoulos)
  - Childhood occipital visual epilepsy
  - Photosensitive occipital lobe epilepsy

- *Generalized epilepsies:*
  - Childhood absence epilepsy (CAE)
  - Epilepsy with myoclonic absences
  - Epilepsy with eyelid myoclonia (Jeavons syndrome)

- *Developmental and/or Epileptic Encephalopathies (DEE):*
  - Lennox-Gastaut syndrome
  - Epileptic encephalopathy with spike-wave activation in sleep

---

## 4. Electroencephalography (EEG)

### 4.1 Role of EEG in Pediatric Epilepsy

EEG is essential for:
- Confirming epileptic nature of events
- Classifying seizure/epilepsy type
- Identifying epilepsy syndrome
- Localizing epileptogenic zone
- Monitoring treatment response

### 4.2 Age-Dependent Normal EEG Patterns

Understanding normal EEG maturation is critical for accurate interpretation. The [NCBI developmental EEG resource](https://www.ncbi.nlm.nih.gov/books/NBK390356/) provides comprehensive guidance.

#### Posterior Dominant Rhythm (PDR) Development

| Age | PDR Frequency | Key Features |
|-----|---------------|--------------|
| Newborn | No PDR | Discontinuous, trace alternant in sleep |
| 3 months | 3-4 Hz | Emerging rhythmicity |
| 6 months | 4-5 Hz | PDR established |
| 12 months | 5-6 Hz | Increasing organization |
| 2 years | 6-7 Hz | Better defined PDR |
| 3 years | 7-8 Hz | Approaching alpha range |
| 8-9 years | 8-9 Hz | Near-adult frequencies |
| 10-12 years | 9-10 Hz | Adult-like pattern |

#### Age Group Classifications

| Age Group | Age Range | EEG Characteristics |
|-----------|-----------|---------------------|
| Neonate | 0-1 month | Rapid changes every 2 weeks in preterm |
| Infant | 1-12 months | Changes monthly |
| Toddler | 1-3 years | Changes yearly |
| Preschool | 3-6 years | Gradual maturation |
| School-age | 6-12 years | Approaches adult pattern |
| Adolescent | 13-18 years | Adult-like, 10 Hz alpha |

### 4.3 Normal Variants (Not to be Misinterpreted as Abnormal)

| Pattern | Description | Clinical Significance |
|---------|-------------|----------------------|
| **Posterior slow waves of youth** | Intermixed delta in posterior regions | Normal until age 12 |
| **Mu rhythm** | Central arciform 8-10 Hz | Blocked by movement/thought |
| **Lambda waves** | Posterior sharp transients | Present with visual scanning |
| **Hypnagogic hypersynchrony** | High-amplitude theta in drowsiness | Normal in children |
| **Vertex waves** | Sharp transients at Cz in sleep | Normal Stage N2 |

### 4.4 Pathological EEG Patterns

#### Interictal Epileptiform Discharges (IEDs)

| Pattern | Associated Syndrome |
|---------|---------------------|
| Centrotemporal spikes | Self-limited epilepsy with centrotemporal spikes |
| 3 Hz spike-wave | Childhood absence epilepsy |
| Hypsarrhythmia | Infantile spasms (West syndrome) |
| Slow spike-wave (<2.5 Hz) | Lennox-Gastaut syndrome |
| Generalized polyspike-wave | Juvenile myoclonic epilepsy |
| Focal spikes/sharp waves | Focal epilepsy |

---

## 5. Seizures in the Genetic Era

### 5.1 The Genetic Architecture of Epilepsy

Approximately **40% of epilepsies** have a significant genetic component. The landmark paper by [Manolio et al. (Nature, 2009)](https://www.nature.com/articles/nature08494) introduced the concept of "missing heritability."

#### Types of Genetic Variants

| Type | Frequency | Effect Size | Detection Method |
|------|-----------|-------------|------------------|
| Common variants | >1% in population | Small | GWAS |
| Rare variants | <1% in population | Large | Sequencing |
| De novo mutations | Unique to individual | Variable | Trio WES/WGS |
| Copy number variants | Variable | Variable | Microarray, WGS |

### 5.2 Major Epilepsy Genes

The following genes are most frequently implicated in genetic epilepsies:

#### Ion Channel Genes

| Gene | Channel | Phenotype | Inheritance |
|------|---------|-----------|-------------|
| **SCN1A** | Nav1.1 | Dravet syndrome, GEFS+ | AD (often de novo) |
| **SCN2A** | Nav1.2 | Early infantile DEE, BFNIS | AD |
| **SCN8A** | Nav1.6 | Early infantile DEE | AD (de novo) |
| **KCNQ2** | Kv7.2 | BFNE, KCNQ2-DEE | AD |
| **KCNT1** | KNa1.1 | EIMFS, ADNFLE | AD |

#### Synaptic Function Genes

| Gene | Function | Phenotype |
|------|----------|-----------|
| **STXBP1** | Synaptic vesicle release | Ohtahara, West syndrome, DEE |
| **SYNGAP1** | Synaptic plasticity | ID with epilepsy |
| **CDKL5** | Kinase signaling | CDKL5-DEE, atypical Rett |
| **PCDH19** | Cell adhesion | PCDH19-clustering epilepsy (females) |

#### Gene Prevalence (per live births)

Based on recent epidemiological data:
- **PRRT2**: 1 per 9,970
- **SCN1A**: 1 per 12,200
- **KCNQ2**: 1 per 17,000
- **SLC2A1**: 1 per 24,300

### 5.3 Developmental and Epileptic Encephalopathies (DEEs)

DEEs are severe conditions where both the underlying etiology and epileptic activity contribute to developmental impairment. [Over 800 genes](https://www.sciencedirect.com/science/article/abs/pii/S2352464224001962) have been implicated in DEEs.

#### Key DEE Genes and Clinical Features

| Gene | Key Features | Treatment Considerations |
|------|--------------|-------------------------|
| **SCN1A** | Fever-triggered seizures, myoclonic jerks | AVOID sodium channel blockers |
| **KCNQ2** | Neonatal onset, tonic seizures | Sodium channel blockers EFFECTIVE |
| **STXBP1** | Variable phenotype, movement disorders | Levetiracetam may help |
| **CDKL5** | Early onset, stereotypies (~79%) | Limited ASM efficacy |

---

## 6. Medical Evaluation and Diagnostic Workup

### 6.1 First Seizure Evaluation Algorithm

```
FIRST UNPROVOKED SEIZURE
           ‚îÇ
           ‚ñº
‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
‚îÇ  IMMEDIATE ASSESSMENT        ‚îÇ
‚îÇ  ‚Ä¢ ABC, vitals, glucose      ‚îÇ
‚îÇ  ‚Ä¢ Detailed history          ‚îÇ
‚îÇ  ‚Ä¢ Neurological examination  ‚îÇ
‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
           ‚îÇ
           ‚ñº
‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
‚îÇ  RED FLAGS? (Emergent imaging)‚îÇ
‚îÇ  ‚Ä¢ Prolonged postictal state ‚îÇ
‚îÇ  ‚Ä¢ Focal deficits            ‚îÇ
‚îÇ  ‚Ä¢ Signs of elevated ICP     ‚îÇ
‚îÇ  ‚Ä¢ History of trauma         ‚îÇ
‚îÇ  ‚Ä¢ Immunocompromised         ‚îÇ
‚îÇ  ‚Ä¢ Age < 6 months            ‚îÇ
‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
           ‚îÇ
    ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¥‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
    ‚ñº             ‚ñº
   YES           NO
    ‚îÇ             ‚îÇ
    ‚ñº             ‚ñº
 CT/MRI        Outpatient
 (emergent)    EEG + MRI
```

### 6.2 When to Image

Based on [clinical pathway guidelines](https://www.chop.edu/clinical-pathway/unprovoked-seizure-clinical-pathway):

#### Emergent Imaging Indicated

- Prolonged postictal confusion (>30 minutes)
- Persistent focal neurological deficit
- Signs of elevated intracranial pressure
- History of significant head trauma
- Immunocompromised state
- Concern for abuse
- Age < 6 months with symptomatic seizure

#### Emergent Imaging NOT Required

- Returned to baseline
- Non-focal examination
- Recognized epilepsy syndrome (e.g., CAE, SLECTS)
- Simple febrile seizure

#### Imaging Modality Selection

| Modality | Indication | Advantages |
|----------|------------|------------|
| **CT Head** | Acute trauma, hemorrhage | Fast, widely available |
| **MRI Brain (epilepsy protocol)** | All other epilepsy workup | Superior soft tissue detail |

### 6.3 Laboratory Evaluation

#### Routine Studies

| Test | Indication |
|------|------------|
| Glucose | All seizures |
| Electrolytes (Na, Ca, Mg) | Suspected metabolic cause |
| CBC with differential | Infection suspected |
| Toxicology screen | Altered mental status, adolescents |

#### Extended Metabolic Workup

Consider when:
- Developmental regression
- Family history of metabolic disease
- Specific seizure types (myoclonic, infantile spasms)
- Refractory epilepsy

| Test | Target Conditions |
|------|-------------------|
| Lactate, pyruvate | Mitochondrial disorders |
| Amino acids (plasma) | Aminoacidopathies |
| Organic acids (urine) | Organic acidemias |
| Ammonia | Urea cycle disorders |
| CSF studies | GLUT1 deficiency, neurotransmitter disorders |

### 6.4 Genetic Testing Strategy

Reference: [McTague et al., The Lancet Neurology (2016)](https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(15)00283-2/fulltext)

#### Testing Algorithm

```
SUSPECTED GENETIC EPILEPSY
           ‚îÇ
           ‚ñº
‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
‚îÇ STEP 1: Chromosomal Microarray  ‚îÇ
‚îÇ (Detect CNVs, aneuploidy)       ‚îÇ
‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
           ‚îÇ
    Normal ‚îÇ
           ‚ñº
‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
‚îÇ STEP 2: Gene Panel or WES       ‚îÇ
‚îÇ Consider clinical presentation: ‚îÇ
‚îÇ ‚Ä¢ Specific syndrome ‚Üí Panel     ‚îÇ
‚îÇ ‚Ä¢ Unknown etiology ‚Üí WES        ‚îÇ
‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
           ‚îÇ
    Normal ‚îÇ
           ‚ñº
‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
‚îÇ STEP 3: WGS, RNA-seq, or        ‚îÇ
‚îÇ Functional studies              ‚îÇ
‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
```

#### Clinical Impact of Genetic Diagnosis

Finding the molecular cause leads to management changes in **36% of patients** with DEEs, including:
- Medication optimization
- Avoidance of harmful drugs
- Targeted therapy selection
- Accurate prognosis
- Genetic counseling

---

## 7. Physical Examination and Phenotyping

### 7.1 Importance of Systematic Phenotyping

Systematic phenotyping:
- Guides genetic test selection
- Enables genotype-phenotype correlation
- Facilitates syndrome recognition
- Improves diagnostic yield

### 7.2 Standardized Terminology Resources

#### Human Phenotype Ontology (HPO)

The [Human Phenotype Ontology](https://hpo.jax.org/) provides standardized vocabulary for phenotype description.

**Key Features:**
- Over 16,000 terms organized hierarchically
- Directly integrated with genomic databases
- Supports computational phenotype matching
- Updated annually with expansions for neurology

#### NIH Elements of Morphology

[Elements of Morphology](https://elementsofmorphology.nih.gov) provides standardized definitions for dysmorphic features with photographic examples.

### 7.3 Systematic Examination Checklist

#### Growth Parameters

- [ ] Head circumference (microcephaly/macrocephaly)
- [ ] Height and weight
- [ ] Growth trajectory over time

#### Craniofacial Features

| Region | Features to Assess |
|--------|-------------------|
| Skull | Shape, fontanelles, sutures |
| Face | Symmetry, proportions |
| Eyes | Spacing, slant, epicanthal folds |
| Nose | Bridge, tip, nares |
| Ears | Position, rotation, morphology |
| Mouth | Philtrum, lip thickness, palate |

#### Skin Examination (Neurocutaneous Markers)

| Finding | Associated Condition |
|---------|---------------------|
| Hypopigmented macules (ash-leaf spots) | Tuberous sclerosis |
| Caf√©-au-lait spots (‚â•6) | Neurofibromatosis type 1 |
| Facial angiofibromas | Tuberous sclerosis |
| Port-wine stain (V1 distribution) | Sturge-Weber syndrome |
| Hyperpigmentation (whorled) | Incontinentia pigmenti |

#### Neurological Examination

- [ ] Mental status and development level
- [ ] Cranial nerves
- [ ] Motor: tone, strength, reflexes
- [ ] Sensory examination
- [ ] Coordination and gait
- [ ] Involuntary movements

---

## 8. Precision Medicine in Epilepsy

### 8.1 The Promise of Precision Therapy

Precision medicine aims to match treatment to the underlying molecular mechanism. Reference: [PMC article on precision medicine in epilepsy](https://pmc.ncbi.nlm.nih.gov/articles/PMC9561034/)

### 8.2 Gene-Specific Treatment Strategies

#### SCN1A (Dravet Syndrome) - Critical Safety Information

**‚ö†Ô∏è MEDICATIONS TO AVOID:**

| Drug Class | Specific Drugs | Reason |
|------------|---------------|--------|
| Sodium channel blockers | Phenytoin, Carbamazepine, Oxcarbazepine, Lamotrigine, Lacosamide, Rufinamide | Worsen seizures and status epilepticus |
| GABA modulators | Vigabatrin, Tiagabine | May worsen seizures |

Reference: [Dravet Syndrome Foundation - Medications to Avoid](https://dravetsyndromenews.com/medications-to-avoid-dravet-syndrome/)

**‚úì RECOMMENDED TREATMENTS:**

1. **First-line**: Valproate + Clobazam
2. **Add-on**: Stiripentol, Cannabidiol, Fenfluramine
3. **Rescue**: Benzodiazepines (NOT phenytoin/fosphenytoin)

#### KCNQ2-Related Epilepsy

Based on the [KCNQ2 paradigm for precision medicine](https://jtggjournal.com/article/view/3566):

| Variant Type | Mechanism | Treatment |
|--------------|-----------|-----------|
| Loss of function (LOF) | Reduced channel activity | Sodium channel blockers EFFECTIVE |
| Gain of function (GOF) | Increased channel activity | Sodium channel blockers optimal |

**First-line**: Carbamazepine, Oxcarbazepine, Phenytoin

#### STXBP1-DEE

- **Levetiracetam**: Good response in 6/8 patients
- **Vigabatrin**: Effective for epileptic spasms (4/5 patients)

### 8.3 Emerging Therapies

| Approach | Target | Status |
|----------|--------|--------|
| Antisense oligonucleotides (ASO) | SCN1A (Dravet) | Clinical trials |
| Gene therapy (ETX101) | SCN1A | Clinical trials |
| CRISPR/dCas9 | SCN1A upregulation | Preclinical |
| Ezogabine/Retigabine | KCNQ2 | Compassionate use |

---

## 9. Clinical Pearls and Pitfalls

### 9.1 Diagnostic Pearls

| Pearl | Application |
|-------|-------------|
| "Fever + prolonged seizure in infant = think SCN1A" | Early genetic testing in suspected Dravet |
| "Neonatal seizures with burst suppression = think STXBP1, KCNQ2" | Guide urgent genetic testing |
| "Seizures only in females with variable severity = think PCDH19" | X-linked pattern |
| "Glucose low in CSF with normal blood glucose = think GLUT1" | SLC2A1 testing, ketogenic diet |

### 9.2 Common Pitfalls to Avoid

| Pitfall | Consequence | Prevention |
|---------|-------------|------------|
| Starting sodium channel blocker without genetic diagnosis | Worsening in Dravet syndrome | Consider genetic testing early |
| Misinterpreting normal EEG variants as epileptiform | Overdiagnosis, unnecessary treatment | Know age-appropriate patterns |
| Skipping developmental history | Missing DEE diagnosis | Always assess milestones |
| Ignoring family history | Missing inherited syndromes | Three-generation pedigree |

### 9.3 Emergency Considerations

**For patients with known Dravet syndrome or suspected SCN1A mutation:**

```
‚ö†Ô∏è IN STATUS EPILEPTICUS:
‚úì USE: Benzodiazepines (lorazepam, diazepam, midazolam)
‚úì USE: Valproate IV
‚úó AVOID: Phenytoin/Fosphenytoin
‚úó AVOID: Lacosamide
```

---

## 10. Summary: Approach to Pediatric Neurologic Diseases

### Etiology Framework

Pediatric neurologic diseases are caused by:

```
‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
‚îÇ              ETIOLOGICAL CATEGORIES             ‚îÇ
‚îú‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î§
‚îÇ  üß¨ GENETIC                                     ‚îÇ
‚îÇ     ‚Ä¢ Monogenic (SCN1A, KCNQ2, STXBP1...)      ‚îÇ
‚îÇ     ‚Ä¢ Chromosomal (Down, Angelman...)           ‚îÇ
‚îÇ     ‚Ä¢ Complex inheritance                       ‚îÇ
‚îú‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î§
‚îÇ  ‚öóÔ∏è  METABOLIC                                  ‚îÇ
‚îÇ     ‚Ä¢ Inborn errors of metabolism               ‚îÇ
‚îÇ     ‚Ä¢ Mitochondrial disorders                   ‚îÇ
‚îÇ     ‚Ä¢ Storage diseases                          ‚îÇ
‚îú‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î§
‚îÇ  ü¶† INFECTIOUS                                  ‚îÇ
‚îÇ     ‚Ä¢ Meningitis/Encephalitis                   ‚îÇ
‚îÇ     ‚Ä¢ Congenital infections (TORCH)             ‚îÇ
‚îÇ     ‚Ä¢ Post-infectious                           ‚îÇ
‚îú‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î§
‚îÇ  üåç ENVIRONMENTAL                               ‚îÇ
‚îÇ     ‚Ä¢ Hypoxic-ischemic injury                   ‚îÇ
‚îÇ     ‚Ä¢ Toxic exposures                           ‚îÇ
‚îÇ     ‚Ä¢ Trauma                                    ‚îÇ
‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
```

### Clinical Approach Checklist

#### 1. Comprehensive History

- [ ] **Prenatal**: Exposures, infections, fetal movements
- [ ] **Perinatal**: Delivery complications, APGAR scores, NICU stay
- [ ] **Postnatal**: Developmental milestones, regression
- [ ] **Seizure history**: Detailed semiology
- [ ] **Family history**: Three-generation pedigree, consanguinity

#### 2. Physical Examination

- [ ] General: Growth parameters, dysmorphic features
- [ ] Skin: Neurocutaneous stigmata
- [ ] Neurological: Complete examination
- [ ] Developmental assessment

#### 3. Investigations

- [ ] EEG (routine, prolonged if needed)
- [ ] Neuroimaging (MRI with epilepsy protocol)
- [ ] Genetic testing (guided by phenotype)
- [ ] Metabolic workup (when indicated)

#### 4. Diagnosis and Management

- [ ] Classify seizure and epilepsy type (ILAE)
- [ ] Identify epilepsy syndrome if possible
- [ ] Select treatment based on diagnosis
- [ ] Avoid contraindicated medications
- [ ] Genetic counseling when applicable

---

## 11. Learning Objectives and Self-Assessment

### Learning Objectives

After completing this lecture, students should be able to:

1. ‚úì Define seizure, epilepsy, and status epilepticus
2. ‚úì Apply the ILAE classification system
3. ‚úì Interpret age-appropriate EEG findings
4. ‚úì List major epilepsy genes and their associated phenotypes
5. ‚úì Outline the diagnostic workup for first seizure
6. ‚úì Perform systematic phenotyping using standardized terminology
7. ‚úì Recognize when genetic testing is indicated
8. ‚úì Identify gene-specific treatment considerations
9. ‚úì Avoid medications contraindicated in specific genetic epilepsies

### Self-Assessment Questions

<details>
<summary><b>Question 1:</b> A 6-month-old presents with recurrent prolonged seizures triggered by fever. Genetic testing reveals an SCN1A mutation. Which medication should be AVOIDED?</summary>

**Answer**: Sodium channel blockers (phenytoin, carbamazepine, lamotrigine, oxcarbazepine, lacosamide) should be avoided as they worsen seizures in Dravet syndrome.
</details>

<details>
<summary><b>Question 2:</b> What is the expected posterior dominant rhythm frequency for a healthy 3-year-old?</summary>

**Answer**: 7-8 Hz. PDR matures from 4-5 Hz at 6 months to adult frequencies (9-10 Hz) by age 10-12 years.
</details>

<details>
<summary><b>Question 3:</b> A neonate presents with tonic seizures on day 3 of life. EEG shows burst-suppression. Which genes should be prioritized for testing?</summary>

**Answer**: STXBP1, KCNQ2, and SCN2A are major causes of early-onset DEE with burst-suppression pattern.
</details>

<details>
<summary><b>Question 4:</b> When is emergent neuroimaging indicated after a first unprovoked seizure?</summary>

**Answer**: Emergent imaging is indicated for: prolonged postictal state (>30 min), persistent focal deficits, signs of elevated ICP, history of trauma, immunocompromised status, or age <6 months with symptomatic seizure.
</details>

<details>
<summary><b>Question 5:</b> What is the first-line treatment for KCNQ2-related epilepsy?</summary>

**Answer**: Sodium channel blockers (carbamazepine, oxcarbazepine) are first-line for KCNQ2-related epilepsy, in contrast to Dravet syndrome where they are contraindicated.
</details>

---

## 12. References and Further Reading

### Key References

1. **ILAE Classification**
   - [ILAE Definition & Classification Portal](https://www.ilae.org/guidelines/definition-and-classification)
   - Specchio N, et al. ILAE classification of childhood epilepsy syndromes. *Epilepsia* 2022
   - [Updated Classification of Epileptic Seizures (2025)](https://onlinelibrary.wiley.com/doi/10.1111/epi.18338)

2. **Pediatric EEG**
   - [NCBI Bookshelf: Developmental EEG](https://www.ncbi.nlm.nih.gov/books/NBK390356/)
   - [LearningEEG.com Pediatric Resources](https://www.learningeeg.com/pediatric)
   - [ACNS Minimum Technical Standards for Pediatric EEG](https://www.acns.org/UserFiles/file/Guideline5-MinimumTechnicalStandardsforPediatricEEG_v1.pdf)

3. **Genetic Epilepsies**
   - McTague A, et al. The genetic landscape of the epileptic encephalopathies. *Lancet Neurology* 2016
   - [Precision medicine in KCNQ2 epilepsy](https://jtggjournal.com/article/view/3566)
   - [DEE therapeutic consequences](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006352/)

4. **Phenotyping Resources**
   - [Human Phenotype Ontology (HPO)](https://hpo.jax.org/)
   - [NIH Elements of Morphology](https://elementsofmorphology.nih.gov)

5. **Clinical Guidelines**
   - [CHOP Unprovoked Seizure Clinical Pathway](https://www.chop.edu/clinical-pathway/unprovoked-seizure-clinical-pathway)
   - [Dravet Syndrome Treatment Guide](https://pmc.ncbi.nlm.nih.gov/articles/PMC8927048/)

### Suggested Textbooks

- Swaiman's Pediatric Neurology (6th edition)
- Pediatric Epilepsy (Pellock, Nordli, Sankar, Wheless)
- Atlas of Pediatric EEG (Blume, Kaibara, Young)

### Online Resources

| Resource | URL | Description |
|----------|-----|-------------|
| ILAE | ilae.org | Classification, guidelines |
| HPO | hpo.jax.org | Phenotype terminology |
| OMIM | omim.org | Gene-disease relationships |
| GeneReviews | ncbi.nlm.nih.gov/books/NBK1116/ | Clinical genetic summaries |
| ClinVar | ncbi.nlm.nih.gov/clinvar/ | Variant interpretation |

---

## Acknowledgments

This lecture material is prepared for medical student education at Korea University Medical Center (KUMC), Department of Pediatric Neurology.

---

## Version History

| Version | Date | Changes |
|---------|------|---------|
| 1.0 | 2023-10-23 | Initial student lecture |
| 2.0 | 2024-12 | Comprehensive update with genetic era content, ILAE 2022/2025 classification, precision medicine |

---

*This document is intended for educational purposes. Clinical decisions should be based on individual patient assessment and current guidelines.*

**License**: This work is licensed under [CC BY-NC-SA 4.0](https://creativecommons.org/licenses/by-nc-sa/4.0/)

---

*Document source: Adapted from lecture slides (231023 ÌïôÏÉùÍ∞ïÏùòÏö©.pptx) with comprehensive updates*
